Back to Authors

Tanner, Caroline M.

0000-0002-3775-5082

Mayo Clinic

Parkinson's Institute

Citations 14

The past, present, and future of telemedicine for Parkinson's disease
Achey, Meredith A. , Aldred, Jason , Aljehani, Noha, Bloem, Bastiaan R. , Biglan, Kevin , Chan, Piu, Cubo, Esther , Dorsey, E. Ray , Guttman, Mark, Hassan, Anhar , Khandhar, Suketu M., Spindler, Meredith , Haak, Pieter van den , Walker, Richard , Wilkinson, Jayne , Force, on behalf of the International Parkinson and Movement Disorder Society Telemedicine Task, Goetz, Christopher G. , Mari, Zoltan K. , Tanner, Caroline M. , Force, on behalf of the International Parkinson and Movement Disorder Society Telemedicine Task

Movement Disorders | May 17, 2014 | Volume: 29 | Issue: 7 | Pages: 871-883

10.1002/mds.25903 Get It

ABSTRACT Travel distance, growing disability, and uneven distribution of doctors limit access to care for most Parkinson's disease (PD) patients worldwide. Telemedicine, the use of telecommunications technology to deliver care at a distance, can help overcome these barriers. In this report, we describe the past, present, and likely future applications of telemedicine to PD. Historically, telemedicine has relied on expensive equipment to connect single patients to a specialist in pilot programs in wealthy nations. As the cost of video conferencing has plummeted, these efforts have expanded in scale and scope, now reaching larger parts of the world and extending the focus from care to training of remote providers. Policy, especially limited reimbursement, currently hinders the growth and adoption of these new care models. As these policies change and technology advances and spreads, the following will likely develop: integrated care networks that connect patients to a wide range of providers; education programs that support patients and health care providers; and new research applications that include remote monitoring and remote visits. Together, these developments will enable more individuals with PD to connect to care, increase access to expertise for patients and providers, and allow more‐extensive, less‐expensive participation in research. © 2014 International Parkinson and Movement Disorder Society
Research on the Premotor Symptoms of Parkinson’s Disease: Clinical and Etiological Implications
Chen, Honglei , Ross, G. Webster , Huang, Xuemei , Savica, Rodolfo , Abbott, Robert D. , Ascherio, Alberto , Caviness, John N., Gao, Xiang , Gray, Kimberly , Hong, Jau‐Shyong , Kamel, Freya , Jennings, Danna , Kirshner, Annette, Lawler, Cindy P., Liu, Rui , Nussbaum, Robert , Peddada, Shyamal D. , Rick, Amy Comstock, Ritz, Beate , Siderowf, Andrew , Tröster, Alexander I. , Zhang, Jing , Burton, Edward A. , Miller, Gary W. , Tanner, Caroline M.

Environmental Health Perspectives | August 9, 2013 | Volume: 121 | Issue: 11-12 | Pages: 1245-1252

10.1289/ehp.1306967 Get It

Abstract Background: The etiology and natural history of Parkinson’s disease (PD) are not well understood. Some non-motor symptoms such as hyposmia, rapid eye movement sleep behavior disorder, and constipation may develop during the prodromal stage of PD and precede PD diagnosis by years. Objectives: We examined the promise and pitfalls of research on premotor symptoms of PD and developed priorities and strategies to understand their clinical and etiological implications. Methods: This review was based on a workshop, Parkinson’s Disease Premotor Symptom Symposium, held 7–8 June 2012 at the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina. Discussion: Research on premotor symptoms of PD may offer an excellent opportunity to characterize high-risk populations and to better understand PD etiology. Such research may lead to evaluation of novel etiological hypotheses such as the possibility that environmental toxicants or viruses may initiate PD pathogenesis in the gastrointestinal tract or olfactory bulb. At present, our understanding of premotor symptoms of PD is in its infancy and faces many obstacles. These symptoms are often not specific to PD and have low positive predictive value for early PD diagnosis. Further, the pathological bases and biological mechanisms of these premotor symptoms and their relevance to PD pathogenesis are poorly understood. Conclusion: This is an emerging research area with important data gaps to be filled. Future research is needed to understand the prevalence of multiple premotor symptoms and their etiological relevance to PD. Animal experiments and mechanistic studies will further understanding of the biology of these premotor symptoms and test novel etiological hypothesis. Citation: Chen H, Burton EA, Ross GW, Huang X, Savica R, Abbott RD, Ascherio A, Caviness JN, Gao X, Gray KA, Hong JS, Kamel F, Jennings D, Kirshner A, Lawler C, Liu R, Miller GW, Nussbaum R, Peddada SD, Comstock Rick A, Ritz B, Siderowf AD, Tanner CM, Tröster AI, Zhang J. 2013. Research on the premotor symptoms of Parkinson’s Disease: clinical and etiological implications. Environ Health Perspect 121:1245–1252; http://dx.doi.org/10.1289/ehp.1306967
Research priorities in spasmodic dysphonia
Ludlow, Christy L. , Berke, Gerald S. , Bielamowicz, Steven , Blitzer, Andrew , Bressman, Susan , Jinnah, H. A. , Juergens, Uwe R., Martin, Sandra B., Sapienza, Christine M. , Woodson, Gayle E. , Adler, Charles H. , Hallett, Mark , Perlmutter, Joel S. , Singleton, Andrew T. , Tanner, Caroline M.

Otolaryngology–Head and Neck Surgery | September 25, 2008 | Volume: 139 | Issue: 4 | Pages: 495-505

10.1016/j.otohns.2008.05.624 Get It

ObjectiveTo identify research priorities to increase understanding of the pathogenesis, diagnosis, and improved treatment of spasmodic dysphonia.Study Design and SettingA multidisciplinary working group was formed that included both scientists and clinicians from multiple disciplines (otolaryngology, neurology, speech pathology, genetics, and neuroscience) to review currently available information on spasmodic dysphonia and to identify research priorities.ResultsOperational definitions for spasmodic dysphonia at different levels of certainty were recommended for diagnosis and recommendations made for a multicenter multidisciplinary validation study.ConclusionsThe highest priority is to characterize the disorder and identify risk factors that may contribute to its onset. Future research should compare and contrast spasmodic dysphonia with other forms of focal dystonia. Development of animal models is recommended to explore hypotheses related to pathogenesis. Improved understanding of the pathophysiology of spasmodic dysphonia should provide the basis for developing new treatment options and exploratory clinical trials.SignificanceThis document should foster future research to improve the care of patients with this chronic debilitating voice and speech disorder by otolaryngology, neurology, and speech pathology.
Meeting Report: Consensus Statement—Parkinson’s Disease and the Environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007
Bronstein, Jeff M. , Carvey, Paul M., Chen, Honglei , Cory‐Slechta, Deborah A. , Monte, Donato A. Di , Duda, John E. , English, Paul , Goldman, Samuel M. , Grate, Stephen J., Hoppin, Jane A. , Jewell, Sarah A. , Kamel, Freya , Langston, J. William, Logroscino, Giancarlo , Nelson, Lorene M. , Ravina, Bernard, Rocca, Walter A. , Ross, G. Webster, Schettler, Ted, Schwarzschild, Michael A. , Scott, Bill, Seegal, Richard F., Singleton, Andrew , Steenland, Kyle , Eeden, Stephen Van Den, Weisskopf, Marc G. , Hansen, Johnni , Koroshetz, Walter J. , Tanner, Caroline M. , Logroscino, Giancarlo

Environmental Health Perspectives | August 25, 2008 | Volume: 117 | Issue: 1 | Pages: 117-121

10.1289/ehp.11702 Get It

Abstract Background Parkinson’s disease (PD) is the second most common neurodegenerative disorder. People with PD, their families, scientists, health care providers, and the general public are increasingly interested in identifying environmental contributors to PD risk. Methods In June 2007, a multidisciplinary group of experts gathered in Sunnyvale, California, USA, to assess what is known about the contribution of environmental factors to PD. Results We describe the conclusions around which they came to consensus with respect to environmental contributors to PD risk. We conclude with a brief summary of research needs. Conclusions PD is a complex disorder, and multiple different pathogenic pathways and mechanisms can ultimately lead to PD. Within the individual there are many determinants of PD risk, and within populations, the causes of PD are heterogeneous. Although rare recognized genetic mutations are sufficient to cause PD, these account for < 10% of PD in the U.S. population, and incomplete penetrance suggests that environmental factors may be involved. Indeed, interplay among environmental factors and genetic makeup likely influences the risk of developing PD. There is a need for further understanding of how risk factors interact, and studying PD is likely to increase understanding of other neurodegenerative disorders.